A Phase Ib Trial of MVA-EBNA1/LMP2 Vaccine in Nasopharyngeal Carcinoma
Status:
Completed
Trial end date:
2017-03-10
Target enrollment:
Participant gender:
Summary
This clinical study is looking at a vaccine called MVA-EBNA1/LMP2. This is a new vaccine that
has already been studied in small number of cancer patients.
The vaccine is designed to boost a patient's immunity against a common virus. The virus is
called Epstein Barr virus or EBV. EBV is sometimes found inside cancer cells and is commonly
found in nasopharyngeal cancer cells.